Anticoagulation Hub

Anticoagulation Hub contains news & clinical reviews for physicians seeking info on treatment options for preventing stroke, ACS, DVT & PE in at-risk patients.

[Anticoagulation Hub @AnticoagHub]

Medical quality beats patient comfort: A good way to survive an acute myocardial infarction is to go to the b... https://t.co/rd0GM9dG2l

[Anticoagulation Hub @AnticoagHub]

Planning, education smooth transition to longer-acting clotting factors: ORLANDO – Transitioning patients wit... https://t.co/VQyRfzNjP7

[Anticoagulation Hub @AnticoagHub]

Early intensive prophylaxis provides better QoL in hemophilia: ORLANDO – Boys with hemophilia have a better q... https://t.co/suZiBIJzQN

[Anticoagulation Hub @AnticoagHub]

NOACs outpace warfarin for afib anticoagulation: The NOAC revolution has happened.
New oral anticoagulants (N... https://t.co/wUWJtNLaZc

[Anticoagulation Hub @AnticoagHub]

Optimal medical therapy doesn’t affect DAPT efficacy: ROME – Continued dual-antiplatelet therapy beyond 12 mo... https://t.co/ezYAYeEuP6

[Anticoagulation Hub @AnticoagHub]

Obstetric VTE safety recommendations stress routine risk assessment: Routine thromboembolism risk assessment ... https://t.co/i80ErTK1oq

[Anticoagulation Hub @AnticoagHub]

Novel GLP-1 receptor agonist shows reduction in cardiovascular risk: The novel glucagonlike peptide 1 (GLP-1)... https://t.co/ToZGdSOiSw

[Anticoagulation Hub @AnticoagHub]

ANTARCTIC results chill enthusiasm for platelet monitoring: ROME – Measuring platelet function in order to ta... https://t.co/QDJWtBlsgm

[Anticoagulation Hub @AnticoagHub]

Ticagrelor slashes first stroke risk after MI: ROME – Adding ticagrelor at 60 mg twice daily in patients on l... https://t.co/XXO22b98aK

[Anticoagulation Hub @AnticoagHub]

Trials offer lessons despite negative primary endpoints: Conventional wisdom holds that for randomized, contr... https://t.co/LxBXlz11Pn

[Anticoagulation Hub @AnticoagHub]

High free T4 levels linked to sudden cardiac death: Higher levels of free thyroxine are associated with an in... https://t.co/rWdlHr0U6J

[Anticoagulation Hub @AnticoagHub]

Commentary: INR instability in the NOAC era: Progress in the development of new oral anticoagulants (NOACs), ... https://t.co/ksuFN4Z2C5

[Anticoagulation Hub @AnticoagHub]

ENSURE-AF trial supports edoxaban for electrical cardioversion: ROME – Results of the largest-ever randomized... https://t.co/2UkkLuePF4

[Anticoagulation Hub @AnticoagHub]

Andexanet controlled factor Xa inhibitor–related bleeding: The factor Xa antidote andexanet achieved effectiv... https://t.co/w2ap2XZlMX

[Anticoagulation Hub @AnticoagHub]

NSTEMI mortality decline attributed to invasive therapies: Invasive coronary therapies deserve credit for the... https://t.co/zsJex2hGR9

[Anticoagulation Hub @AnticoagHub]

Off-hours timing does not affect PCI outcomes: Off-hours presentation to the hospital with STEMI did not affe... https://t.co/GZXOLQKCt9

[Anticoagulation Hub @AnticoagHub]

VIDEO: ICDs cut mortality in younger, healthier heart failure patients: ROME – Implantable cardioverter-defib... https://t.co/Rib3ZwblVx

[Anticoagulation Hub @AnticoagHub]

Novel treatment strategy to reduce infarct size in STEMI: ROME – Early administration of high-dose N-acetylcy... https://t.co/dsTaZIThuj

[Anticoagulation Hub @AnticoagHub]

Major depressive disorder increases acute MI risk in HIV: Major depressive disorder is associated with a sign... https://t.co/ZbQepHa4qb

[Anticoagulation Hub @AnticoagHub]

VIDEO: NOACs cut intracranial bleeds in real-world atrial fib patients: ROME – The new oral anticoagulants pe... https://t.co/F1Q6GWp9AJ